Halozyme Therapeutics to Release Q3 2024 Results
Halozyme Therapeutics, Inc. (NASDAQ: HALO) has announced it will publish its financial and operational results for the third quarter of 2024 on Thursday, following the market's close. This moment is significant not only for the company but also for its investors and stakeholders eager to learn about the latest updates.
Conference Call Details
On the same day, Halozyme will hold a conference call to further discuss these results. The call is scheduled for 1:30 p.m. PT and 4:30 p.m. ET. Interested participants can access the call live after pre-registration on the company's website. The session promises an engaging discussion about Halozyme's journey during the quarter and what’s ahead.
Innovations in Drug Delivery Technology
At the heart of Halozyme’s operations is their proprietary ENHANZE drug delivery technology, which utilizes the enzyme rHuPH20. This innovative approach facilitates subcutaneous drug delivery, allowing for rapid and less burdensome treatment options for patients. More than 800,000 patients have benefited from this technology, which is utilized in eight commercialized products globally.
Partnerships with Leading Companies
Halozyme has strategically partnered with numerous pharmaceutical and biotechnology firms, including industry giants like Roche, Pfizer, and AbbVie. These collaborations not only highlight the credibility and ambition of Halozyme but also expand the reach of their cutting-edge technology, enhancing treatment experiences for diverse patient populations.
Advancing Patient Care with Drug-Device Combinations
In addition to its drug delivery solutions, Halozyme is actively involved in the development of drug-device combination products. These products leverage advanced auto-injector technologies that improve convenience and reliability for patients. Currently, Halozyme has two proprietary commercial products: Hylenex and XYOSTED, alongside various partnerships and ongoing developments with firms like Teva Pharmaceuticals.
Committed to Improving Patient Outcomes
Halozyme's commitment to enhancing patient comfort and treatment adherence shapes its research and product development strategies. The company's innovative approach in combining drug delivery systems with user-friendly devices positions it well in the biopharmaceutical landscape.
Corporate Information
Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey, and operations facilities located in Minnetonka, Minnesota. With a team dedicated to improving therapeutic outcomes, Halozyme continues to pave the way in the biopharmaceutical sector.
For further details about the company's offerings and initiatives, interested individuals can visit Halozyme's official website. They can also follow their updates through professional networks like LinkedIn and platforms like Twitter.
Frequently Asked Questions
When will Halozyme release its Q3 2024 results?
Halozyme is set to release its third quarter results on a Thursday after the market closes.
What is ENHANZE technology?
ENHANZE is Halozyme's proprietary drug delivery technology aimed at making subcutaneous drug delivery faster and more convenient for patients.
Who are some of Halozyme's key partners?
Halozyme partners with leading companies such as Roche, Pfizer, and AbbVie to enhance its drug delivery solutions.
What products does Halozyme commercialize?
Halozyme has two proprietary products: Hylenex and XYOSTED, and it is involved in several commercial and developmental partnerships.
Where is Halozyme headquartered?
The company is headquartered in San Diego, CA, with additional offices in Ewing, NJ, and Minnetonka, MN.
